• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

柠檬酸他莫昔芬包封的缓释脂质体:制备及理化性质评价

Tamoxifen citrate encapsulated sustained release liposomes: preparation and evaluation of physicochemical properties.

作者信息

Layek Buddhadev, Mukherjee Biswajit

机构信息

Department of Pharmaceutical Technology, Division of Pharmaceutics, Jadavpur University, Kolkata-700032, India.

出版信息

Sci Pharm. 2010 Jul-Sep;78(3):507-15. doi: 10.3797/scipharm.0911-11. Epub 2010 Jul 12.

DOI:10.3797/scipharm.0911-11
PMID:21179362
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3002818/
Abstract

The present study was designed for the development of a stable sustained release liposomal drug delivery system for tamoxifen citrate (TC) using soya phosphatidylcholine (SPC), cholesterol (CH) and span 20 as main ingredients. Liposomes were prepared by formation of thin lipid film followed by hydration. The mean vesicle diameter was found to be 203.5 Â 19.5 nm with 21% of the liposomal population having average diameter below 76.72 Â 6.7 nm. There was a good vesicular distribution with the polydispersity index of 0.442 Â 0.03. The maximum loading of drug was determined to be 53.60% of the initial amount that is 34.58 Îg of drug per mg of lipid. Amongst the different storage conditions, liposomes stored at 2â8ÂC were found to be most stable and only 4% of the drug was lost over the storage period of 5 weeks. In vitro release studies of liposomes showed that 50% of drug was released within 3 hours (h) whereas 95% drug was released in 30 h. This indicates the usefulness of the liposomal delivery system for sustaining the in vitro release of tamoxifen citrate.

摘要

本研究旨在开发一种以大豆磷脂酰胆碱(SPC)、胆固醇(CH)和司盘20为主要成分的用于柠檬酸他莫昔芬(TC)的稳定缓释脂质体药物递送系统。通过形成脂质薄膜然后水化来制备脂质体。发现平均囊泡直径为203.5±19.5nm,21%的脂质体群体平均直径低于76.72±6.7nm。囊泡分布良好,多分散指数为0.442±0.03。药物的最大载药量确定为初始量的53.60%,即每毫克脂质含34.58μg药物。在不同的储存条件中,发现储存在2-8℃的脂质体最稳定,在5周的储存期内仅损失4%的药物。脂质体的体外释放研究表明,50%的药物在3小时内释放,而95%的药物在30小时内释放。这表明脂质体递送系统对于维持柠檬酸他莫昔芬的体外释放是有用的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68d9/3002818/85ffec11bcf8/scipharm.2010.78.507f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68d9/3002818/3e7029ec55be/scipharm.2010.78.507f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68d9/3002818/bd90ddc95405/scipharm.2010.78.507f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68d9/3002818/9b17caa5e43f/scipharm.2010.78.507f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68d9/3002818/85ffec11bcf8/scipharm.2010.78.507f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68d9/3002818/3e7029ec55be/scipharm.2010.78.507f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68d9/3002818/bd90ddc95405/scipharm.2010.78.507f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68d9/3002818/9b17caa5e43f/scipharm.2010.78.507f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68d9/3002818/85ffec11bcf8/scipharm.2010.78.507f4.jpg

相似文献

1
Tamoxifen citrate encapsulated sustained release liposomes: preparation and evaluation of physicochemical properties.柠檬酸他莫昔芬包封的缓释脂质体:制备及理化性质评价
Sci Pharm. 2010 Jul-Sep;78(3):507-15. doi: 10.3797/scipharm.0911-11. Epub 2010 Jul 12.
2
Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation.局部脂质体中的他莫昔芬:研发、表征及体外评价
J Pharm Pharm Sci. 2004 Jul 16;7(2):252-9.
3
A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies.一种用于康普瑞汀A4的靶向脂质体递送系统:通过载药和体外释放研究进行制剂优化
PDA J Pharm Sci Technol. 2006 May-Jun;60(3):144-55.
4
Preparation and characterization of cefditoren pivoxil-loaded liposomes for controlled in vitro and in vivo drug release.用于体外和体内药物控释的头孢妥仑匹酯脂质体的制备与表征
Int J Nanomedicine. 2015 Oct 1;10 Suppl 1(Suppl 1):149-57. doi: 10.2147/IJN.S79994. eCollection 2015.
5
Pulmonary liposomal formulations encapsulated procaterol hydrochloride by a remote loading method achieve sustained release and extended pharmacological effects.肺部脂质体制剂通过远程载入法包裹盐酸丙卡特罗,实现了缓释和延长药理作用。
Int J Pharm. 2016 May 30;505(1-2):139-46. doi: 10.1016/j.ijpharm.2016.03.031. Epub 2016 Mar 21.
6
Liposomal drugs dispersed in hydrogels. Effect of liposome, drug and gel properties on drug release kinetics.分散在水凝胶中的脂质体药物。脂质体、药物和凝胶性质对药物释放动力学的影响。
Colloids Surf B Biointerfaces. 2007 Apr 1;55(2):212-21. doi: 10.1016/j.colsurfb.2006.12.005. Epub 2006 Dec 17.
7
Preclinical study of Doxorubicine-loaded liposomal drug delivery for the treatment of head and neck cancer: Optimization by Box-Behnken statistical design.载多柔比星脂质体药物递药系统治疗头颈部癌症的临床前研究:Box-Behnken 统计设计的优化。
Acta Biochim Pol. 2020 Jun 8;67(2):149-155. doi: 10.18388/abp.2020_5142.
8
Study of ocular drug delivery system using drug-loaded liposomes.使用载药脂质体的眼部给药系统研究。
Int J Pharm Investig. 2011 Jan;1(1):35-41. doi: 10.4103/2230-973X.76727.
9
Preparation, characterization and in vitro evaluation of sterically stabilized liposome containing a naphthalenediimide derivative as anticancer agent.制备、表征和含有萘二酰亚胺衍生物的立体稳定脂质体的体外评价作为抗癌剂。
Drug Deliv. 2015;22(5):590-7. doi: 10.3109/10717544.2013.861042. Epub 2013 Nov 29.
10
Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation.用于吸入的利福平脂质体干粉制剂的物理化学特性及稳定性
J Pharm Sci. 2009 Feb;98(2):628-39. doi: 10.1002/jps.21441.

引用本文的文献

1
QbD-Anchored Preparation and Assessment of Transethosomal Gel for Enhanced Skin Permeation of Tamoxifen Citrate.基于质量源于设计的柠檬酸他莫昔芬经皮传递体凝胶的制备与评价,以增强其皮肤渗透性能
Curr Pharm Des. 2025;31(29):2352-2369. doi: 10.2174/0113816128344198250308022732.
2
Studies on PVP-Based Hydrogel Polymers as Dressing Materials with Prolonged Anticancer Drug Delivery Function.基于聚乙烯吡咯烷酮的水凝胶聚合物作为具有延长抗癌药物递送功能的敷料材料的研究。
Materials (Basel). 2023 Mar 20;16(6):2468. doi: 10.3390/ma16062468.
3
Mechanistic Approach of Nano Carriers for Targeted in Cancer Chemotherapy: A Newer Strategy for Novel Drug Delivery System.

本文引用的文献

1
Sustained release of acyclovir from nano-liposomes and nano-niosomes: an in vitro study.阿昔洛韦从纳米脂质体和纳米非离子表面活性剂泡囊的缓释:一项体外研究。
Int J Nanomedicine. 2007;2(2):213-25.
2
Enhanced drug transport from unilamellar to multilamellar liposomes induced by molecular recognition of their lipid membranes.通过脂质膜的分子识别诱导药物从单层脂质体向多层脂质体的转运增强。
Langmuir. 2005 Jul 19;21(15):6696-702. doi: 10.1021/la050211n.
3
Effects of lipid chain unsaturation and headgroup type on molecular interactions between paclitaxel and phospholipid within model biomembrane.
纳米载体用于癌症化疗靶向治疗的机制研究:新型药物递送系统的新策略
Polymers (Basel). 2022 Jun 8;14(12):2321. doi: 10.3390/polym14122321.
4
Development of stealth liposomal formulation of celecoxib: In vitro and in vivo evaluation.塞来昔布隐形脂质体制剂的研制:体外与体内评价。
PLoS One. 2022 Apr 26;17(4):e0264518. doi: 10.1371/journal.pone.0264518. eCollection 2022.
5
Preparation of Liposomal Raloxifene-Graphene Nanosheet and Evaluation of Its Anticancer Effects.脂质体雷洛昔芬-石墨烯纳米片的制备及其抗癌效果评估
Dose Response. 2022 Jan 12;20(1):15593258211063983. doi: 10.1177/15593258211063983. eCollection 2022 Jan-Mar.
6
Experimental Design Supported Liposomal Aztreonam Delivery: Studies.实验设计支持脂质体氨曲南递送:研究。
Adv Pharm Bull. 2021 Sep;11(4):651-662. doi: 10.34172/apb.2021.074. Epub 2020 Sep 15.
7
Formulation, characterization, and cellular toxicity assessment of tamoxifen-loaded silk fibroin nanoparticles in breast cancer.乳腺癌中载有他莫昔芬的丝素蛋白纳米颗粒的制剂、表征及细胞毒性评估
Drug Deliv. 2021 Dec;28(1):1626-1636. doi: 10.1080/10717544.2021.1958106.
8
Novel Tamoxifen Nanoformulations for Improving Breast Cancer Treatment: Old Wine in New Bottles.新型他莫昔芬纳米制剂改善乳腺癌治疗:旧酒换新瓶。
Molecules. 2020 Mar 5;25(5):1182. doi: 10.3390/molecules25051182.
9
Flurbiprofen-loaded stealth liposomes: studies on the development, characterization, pharmacokinetics, and biodistribution.载有氟比洛芬的隐形脂质体:关于其开发、表征、药代动力学和生物分布的研究
J Young Pharm. 2012 Oct;4(4):209-19. doi: 10.4103/0975-1483.104364.
10
Transfersomes: a novel vesicular carrier for enhanced transdermal delivery of sertraline: development, characterization, and performance evaluation.传递体:一种用于增强舍曲林经皮递送的新型囊泡载体:研发、表征及性能评估
Sci Pharm. 2012 Oct-Dec;80(4):1061-80. doi: 10.3797/scipharm.1208-02. Epub 2012 Aug 31.
脂质链不饱和度和头部基团类型对模型生物膜中紫杉醇与磷脂分子间相互作用的影响。
J Colloid Interface Sci. 2005 May 1;285(1):326-35. doi: 10.1016/j.jcis.2004.11.032.
4
Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation.新型无聚氧乙烯蓖麻油的脂质体紫杉醇(LEP-ETU)制剂的研发与特性研究
Eur J Pharm Biopharm. 2005 Jan;59(1):177-87. doi: 10.1016/j.ejpb.2004.06.009.
5
Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation.局部脂质体中的他莫昔芬:研发、表征及体外评价
J Pharm Pharm Sci. 2004 Jul 16;7(2):252-9.
6
Effects of low dose tamoxifen on normal breast tissue from premenopausal women.低剂量他莫昔芬对绝经前女性正常乳腺组织的影响。
Eur J Cancer. 2003 May;39(7):891-8. doi: 10.1016/s0959-8049(02)00530-0.
7
Anti-oestrogenic chemoprevention of breast cancer-the need to progress.
Eur J Cancer. 2003 Mar;39(5):572-9. doi: 10.1016/s0959-8049(02)00771-2.
8
Chemoprevention of breast cancer: current and future prospects.
Cancer Metastasis Rev. 2002;21(3-4):311-21. doi: 10.1023/a:1021219212638.
9
Biodegradable poly(epsilon -caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen.用于他莫昔芬肿瘤靶向递送的可生物降解聚(ε-己内酯)纳米颗粒。
Int J Pharm. 2002 Dec 5;249(1-2):127-38. doi: 10.1016/s0378-5173(02)00483-0.
10
The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators.他莫昔芬治疗乳腺癌的演变:选择性雌激素受体调节剂和下调剂。
Lancet Oncol. 2002 Apr;3(4):207-14. doi: 10.1016/s1470-2045(02)00711-8.